TG Therapeutics is an innovative, biopharmaceutical company focused on hematological malignancies. Ublituximab is a novel, glycoengineered mAb targeting a unique epitope on the CD20 antigen. Umbralisib is an oral, QD, PI3K delta/CK1 epsilon inhibitor with a differentiated profile. The GENUINE trial (R/R, high-risk CLL = ublitxuimab+IB vs IB. UNITY Trials = U2 (umbralisib & ublituximab) in treatment naïve/previously treated CLL and R/R NHL. Preclin = PD-L1, BTK, Bispecific CD47/CD19, GITR, BET.